Home
Ole-Bjørn Tysnes's picture

Ole-Bjørn Tysnes

Professor
  • E-mailOle-Bjorn.Tysnes@uib.no
  • Phone+47 55 97 50 63
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2019. The value of cerebrospinal fluid alpha-synuclein and the tau/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. European Journal of Neurology. 43-50.
  • 2019. Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. Neurology. e1526-e1534.
  • 2019. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders. 1839-1850.
  • 2019. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurology: Genetics. 1-14.
  • 2019. Evolution of impulsive–compulsive behaviors and cognition in Parkinson’s disease. Journal of Neurology. 259-266.
  • 2019. Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS) in Norway: Protocol for validation and a prospective cohort study. Contemporary Clinical Trials Communications. 1-7.
  • 2019. Combinatory microRNA serum signatures as classifiers of Parkinson's disease. Parkinsonism & Related Disorders. 202-210.
  • 2018. Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. Neurobiology of Aging. 120-127.
  • 2018. Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. Movement Disorders. 1591-1600.
  • 2018. Laryngeal responses to mechanically assisted cough in progressing amyotrophic lateral sclerosis. Respiratory care. 538-549.
  • 2018. Inflammation and fatigue in early, untreated Parkinson's Disease. Acta Neurologica Scandinavica. 394-399.
  • 2018. Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. Acta Neurologica Scandinavica. 508-514.
  • 2018. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. Parkinsonism & Related Disorders. 4-8.
  • 2018. Dopaminergic and opioid pathways associated with impulse control disorders in Parkinson's disease. Frontiers in Neurology. 1-9.
  • 2018. Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's & Dementia. 1293-1301.
  • 2018. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 303-310.
  • 2018. Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. Neuroscience Letters. 123-126.
  • 2018. A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease. Movement Disorders. 298-299.
  • 2017. The natural history of depressive symptoms in patients with incident Parkinson?s disease: a prospective cohort study. Journal of Neurology. 1-8.
  • 2017. The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal. Neuroscience Letters. 48-52.
  • 2017. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
  • 2017. Natural course of mild cognitive impairment in Parkinson disease. Neurology. 767-774.
  • 2017. July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 471-474.
  • 2017. Is fatigue associated with cognitive dysfunction in early Parkinson's disease? Parkinsonism & Related Disorders. 87-91.
  • 2017. Impulsive and Compulsive Behaviors in Parkinson’s Disease: The Norwegian ParkWest Study. Journal of Parkinson's Disease. 183-191.
  • 2017. Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement Disorders. 241-245.
  • 2017. Epidemiology of Parkinson's disease. Journal of Neural Transmission.
  • 2017. Development and validation of prognostic survival models in newly diagnosed Parkinson's disease. Movement Disorders. 108-116.
  • 2017. Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. Parkinsonism & Related Disorders. 28-33.
  • 2017. Bruk av avansert behandling ved Parkinsons sykdom i Norge. Tidsskrift for Den norske legeforening. 619-623.
  • 2016. Validation of a new assay for α-synuclein detection in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine. 254-260.
  • 2016. Utredning ved mistenkt kronisk utmattelsessyndrom/ myalgisk encefalopati. Tidsskrift for Den norske legeforening. 227-232.
  • 2016. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 256-264.
  • 2016. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism & Related Disorders. 48-53.
  • 2016. Reliability of three disability scales for detection of independence loss in Parkinson's Disease. Parkinson's Disease. 1-6.
  • 2016. Mortality trends of amyotrophic lateral sclerosis in Norway 1951–2014: an age–period–cohort study. Journal of Neurology. 1-8.
  • 2016. Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study. Neurology. 1599-1606.
  • 2016. Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. Journal of Neurology. 364-372.
  • 2016. Laryngeal response patterns influence the efficacy of mechanical assisted cough in amyotrophic lateral sclerosis. Thorax. 221-229.
  • 2016. Impact of Falls on Physical Activity in People with Parkinson's Disease. Journal of Parkinson's Disease. 175-182.
  • 2016. Fatigue in early Parkinson's disease: the Norwegian ParkWest study. European Journal of Neurology. 105-111.
  • 2016. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nature Communications. 11 pages.
  • 2016. Changes in insomnia subtypes in early Parkinson disease. Neurology. 352-358.
  • 2015. The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimer's & Dementia. 1407-1416.
  • 2015. HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. Proceedings of the National Academy of Sciences of the United States of America.
  • 2015. Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. Journal of Human Genetics. 357-362.
  • 2015. Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 162-168.
  • 2015. Association of a BACE1 gene polymorphism with Parkinson's disease in a Norwegian population. Parkinson's Disease. 5 pages.
  • 2014. The factor structure of the UPDRS motor scores changes during early Parkinson's disease. Parkinsonism & Related Disorders. 617-621.
  • 2014. Terapianbefaling Parkinsons sykdom. Nyhetsbulletin. 5-29.
  • 2014. Medisinering av Parkinsonpasienter som trenger kirurgisk behandling I generell anestesi. Nyhetsbulletin. 10-11.
  • 2014. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 1784-1790.
  • 2013. Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 23-28.
  • 2013. Treatment in early Parkinson's disease: the Norwegian ParkWest study. Acta Neurologica Scandinavica. 107-113.
  • 2013. Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiology of Aging. 7 pages.
  • 2013. Prognosis of Mild Cognitive Impairment in Early Parkinson Disease. JAMA Neurology. 580-586.
  • 2013. Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism & Related Disorders. 53-55.
  • 2013. Laryngeal response patterns to mechanical insufflation-exsufflation in healthy subjects. American Journal of Physical Medicine & Rehabilitation. 920-929.
  • 2013. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson's disease. Parkinsonism & Related Disorders. 1027-1032.
  • 2013. Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 537-543.
  • 2013. Cerebrospinal fluid A levels correlate with structural brain changes in Parkinson's disease. Movement Disorders. 302-310.
  • 2013. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurologica Scandinavica. 290-294.
  • 2012. White Matter Hyperintensities in Mild Lewy Body Dementia. Dementia and geriatric cognitive disorders extra. 481-495.
  • 2012. Subjective sleep problems in patients with early Parkinson's disease. European Journal of Neurology. 1575-1581.
  • 2012. Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease. The American journal of geriatric psychiatry. 142-148.
  • 2012. Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion (Amsterdam. Print). 640-643.
  • 2012. Novel TARDBP mutations in Nordic ALS patients. Journal of Human Genetics. 316-319.
  • 2012. Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. Journal of the Neurological Sciences. 211-216.
  • 2012. Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. Neurobiology of Aging. 2113-2124.
  • 2012. Fatigue in early Parkinson's disease. Minor inconvenience or major distress? European Journal of Neurology. 963-968.
  • 2012. Comparing Hippocampal Atrophy in Alzheimer's Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders. 44-50.
  • 2011. Verbal memory in drug-naive, newly diagnosed Parkinson's Disease. The retrieval deficit hypothesis revisited. Neuropsychology. 114-124.
  • 2011. Ventricular enlargement and mild cognitive impairment in early Parkinson's Disease. Movement Disorders. 297-301.
  • 2011. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology. 1941-1946.
  • 2011. Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s Disease : frequent but mild. Movement Disorders. 65-72.
  • 2011. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics. 1697-1700.
  • 2010. The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study. Acta Neurologica Scandinavica. 438-441.
  • 2010. Gray matter correlations of cognition in incident Parkinson's disease. Movement Disorders. 629-633.
  • 2010. Differential Effect of Environmental Risk Factors on Postural Instability Gait Difficulties and Tremor Dominant Parkinson's Disease. Movement Disorders. 1847-1852.
  • 2010. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. Acta Neurologica Scandinavica. 418-424.
  • 2010. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery and Psychiatry. 1080-1086.
  • 2010. Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. Journal of Neurology. 217-223.
  • 2009. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage. 2083-2089.
  • 2009. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry. 928-930.
  • 2009. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery and Psychiatry. 851-857.
  • 2009. High Prevalence of Orthostatic Hypotension in Mild Dementia. Dementia and Geriatric Cognitive Disorders. 307-313.
  • 2009. Cognitive impairment in incident, untreated Parkinson disease The Norwegian ParkWest Study. Neurology. 1121-1126.
  • 2009. Brain Atrophy and White Matter Hyperintensities in Early Parkinson's Disease. Movement Disorders. 2233-2241.
  • 2008. Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica. 77-81.
  • 2007. Demens ved Parkinsons sykdom. Tidsskrift for Den norske legeforening. 2517-2520.
  • 2006. Bergen International symposium in neuroimmunology 2006. Introduction. Acta Neurologica Scandinavica, Supplementum. v-vi.
  • 2004. Neuroborreliosis with stroke-like manifestations. European Neurology. 49-50.
  • 2004. Epidemiology and management of ALS. Advances in Clinical Neuroscience & Rehabilitation. 8-9.
  • 2003. Risk of variant Creutzfeldt-Jakob disease and toncillectomy. Archives of Oto-Rhino-Laryngology. 141-144.
  • 2003. GM1-antibodies in post-polio syndrome and previous paralytic polio. Journal of Neuroimmunology. 141-144.
  • 2002. Kraniocervical arteriedisseksjon. Tidsskrift for Den norske legeforening. 2355-2357.
  • 2002. Etiologi og genetikk ved Alzheimers sykdom. Tidsskrift for Den norske legeforening. 50-53.
  • 2002. Cystic Dilatation of Virchow-Robin Spaces in the Midbrain. European Neurology. 186-188.
  • 2001. Hemiballisme ved hjerneinfarkt. Tidsskrift for Den norske legeforening. 2593-2595.
  • 2001. Epidemiology of ALS. Increasing incidence? Profile. 6-7.
  • 2000. Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • 2000. Polynevropati er et tidlig funn ved primært systemisk amyloidose. Tidsskrift for Den norske legeforening. 1291-1293.
  • 2000. Increasing mortality from amyotrophic lateral sclerosis in Norway? Neurology. 1262-1266.
  • 2000. Increasing mortality from amyotrophic lateral sclerosis in Norway? Neurology. 1262-1266.
  • 2000. Diffusjonsvektet magnetisk resonanstomografi - nytt i diagnostikken av Creutzfeldt-Jakob sykdom. Tidsskrift for Den norske legeforening. 675-677.
  • 2000. Diffusjonsvektet magnetisk resonanstomografi - nytt i diagnostikken av Creutzfeldt-Jakob sykdom. Tidsskrift for Den norske legeforening. 675-677.
  • 1999. Dolikoektasi av intrakraniale arterier og hjerneslag. Tidsskrift for Den norske legeforening. 3004-3005.
  • 1999. Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro. Anticancer Research. 149-56.
  • 1998. Expression of annexin II in glioma cell lines and in brain tumor biopsies. Journal of Neuro-Oncology. 11-18.
  • 1998. Dynamic determination of human glioma invasion in vitro. Journal of Neurosurgery. 441-447.
  • 1998. Dynamic determination of human glioma invasion in vitro. Journal of Neurosurgery. 441-447.
  • 1997. Skrapesyke, kugalskap og Creutzfeldt-Jakobs sjukdom. Naturen. 81-90.
  • 1997. Fem års erfaringer med en amyotrofisk lateralsklerose klinikk. Tidsskrift for Den norske legeforening. 1892-1895.
  • 1997. En ny variant av Creutzfeldt-Jakobs sjukdom. Vil vi sjå utvikling av ein epidemi? Tidsskrift for Den norske legeforening. 384-388.
  • 1997. Adhesion and migration of glioma cells are differently dependent on extracellular matrix molecules. Anticancer Research. 1035-1043.
  • 1994. Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. Varicella zoster-infeksjoner og neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. Varicella zoster-infeksjoner of neurologiske komplikasjoner. Tidsskrift for Den norske legeforening. 2484-2486.
  • 1994. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • 1994. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • 1994. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology. 226-235.
  • 1994. Organic solvents activate human platelets through the inositol lipid-linked signal transduction system. Platelets. 266-271.
  • 1994. Organic solvents activate human platelets through the inositol lipid-linked signal tranduction system. Platelets. 266-271.
  • 1994. Hydrophobic organic solvents activate human platelets through inositol lipid metabolism. Platelets. 266-271.
  • 1994. Hydrophobic organic solvents activate human platelets in vitro. Platelets. 193-200.
  • 1994. Hydrophobic organic solvents activate human platelets in vitro. Platelets. 193-200.
  • 1994. Development of methionine dependence in a human glioma cell line. Relation to homocysteine remethylation and cobalamin status. Cancer Research. 4899-4906.
  • 1994. Development of methionine dependence in a human glioma cell line. Relation to homocystein remethylation and cobalamin status. Cancer Research. 4899-4906.
  • 1994. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity. 327-331.
  • 1994. Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis. Autoimmunity. 327-331.
  • 1994. Activation of blood platelets in workers exposed to organic solvents. Platelets. 193-200.
  • 1993. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. Journal of Autoimmunity. 507-515.
  • 1993. IgG subclass distribution of ryanodine receptor autoantibodies in patients with myasthenia gravis and thymoma. Journal of Autoimmunity. 507-515.
  • 1993. Differential effects of 12-O-tetradecanoyl-13-phorbol acetate (TPA) on growth, migration and invasion of a human glioma cell line. Anticancer Research. 1325-1330.
  • 1993. Differential effects of 12-O-tetradecanoyl-13-phorbol acetate (TPA) on growth, migration and invasion of a human glioma cell line. Anticancer Research. 1325-1330.
  • 1993. Betydningen av radiologisk påvist hjernekontusjon for resultatet av hodeskade. Tidsskrift for Den norske legeforening. 1227-1229.
  • 1992. Ryanodine Receptor Autoantibodies in Myasthenia Gravis Patients with a Thymoma. Annals of Neurology. 589-591.
  • 1992. Perifer facialisparese som symptom på infeksjon med Borrelia burgdorferi. Tidsskrift for Den norske legeforening. 50-51.
  • 1992. Inositol phospholipid metabolism in resting and stimulated human platelets. Cellular Signalling. 611-617.
  • 1992. Early and late outcome in head-injured patients with radiological evidence of brain damage. Comparison with patients substaining brain concussion. Acta Neurologica Scandinavica. 194-198.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1992. Activation of blood platelets in workers exposed to organic solvents. J Occ Med. 687-692.
  • 1991. Stimulation of human platelets with low concentrations of thrombin: Evidence for equimolecular formation of inositol triphosphate and phosphatidic acid. International journal of biochemistry. 305-310.
  • 1991. Epidemiology of amytrophic lateral sclerosis in Hordaland County, western Norway. Acta Neurologica Scandinavica. 280-285.
  • 1991. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, Western Norway. Acta Neurologica Scandinavica. 280-285.
  • 1991. Amyotrofisk lateral sklerose; forekomst og prognose. Tidsskrift for Den norske legeforening. 2634-2636.
Academic lecture
  • 2013. I hvilken grad vurderer Nevrologer førerkortforskriften likt.
  • 2013. Førerkortforskriften:Hva betyr de nye reglene for deg som nevrolog?
  • 2002. Do Riluzole or PEG affect survival in ALS.
Reader opinion piece
  • 2017. Hvem skal utrede kronisk utmattelse? Tidsskrift for Den norske legeforening. 21-22.
  • 2016. Re: Utredning ved mistenkt kronisk utmattelsessyndrom : O.B. Tysnes og medarbeidere svarer. Tidsskrift for Den norske legeforening. 892-892.
Short communication
  • 2020. Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden. Parkinsonism & Related Disorders. 27-30.
Popular scientific article
  • 2000. Utredning og behandling av amyotrofisk lateralsklerose. ALS kompendium. 5-9.
  • 2000. Creutzfeldt-Jakobs sykdom i Norge. Demens i allmennpraksis. 1-2.
  • 2000. Creutzfeldt-Jakobs sykdom i Norge. Demens i allmennpraksis. 1-2.
Feature article
  • 2019. Hvor står ALS-forskningen i Norge? VG : Verdens gang.
Letter to the editor
  • 2018. No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. Brain. e16-e16.
  • 2018. Laryngoscopy Can Be a Valuable Tool for Unexpected Therapeutic Response in Noninvasive Respiratory Interventions. Respiratory care. 1459-1461.
  • 2018. Is psychosis associated with impulse control disorders in Parkinson's disease? Parkinsonism & Related Disorders. 110-111.
  • 2015. Does vagotomy reduce the risk of Parkinson's disease? Annals of Neurology. 1011-1012.
Doctoral dissertation
  • 2018. Laryngeal response patterns during mechanically assisted cough in Amyotrophic Lateral Sclerosis.
  • 1988. Cell signalling through inositol phospholipid metabolism : characterization of phosphoinositide metabolism in resting and stimulated human platelets.
Academic chapter/article/Conference paper
  • 2015. Motor Neuron Disease (Amyotrophic Lateral Sclerosis).
  • 2014. Nevrologisk undersøkelse av voksne. 23 pages.
  • 2014. Motornevronsykdommer. 5 pages.
  • 2012. Using local binary pattern to classify dementia in MRI. 4 pages.
  • 2010. Nevrologisk undersøkelse av voksne. 22 pages.
  • 1992. Polyphosphoinositide metabolism in resting and stimulated platelets. 20 pages.
  • 1991. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, Western Norway. 7 pages.
Other
  • 2000. Utredning og behandling av amyotrofisk lateralsklerose. 5-9.
Abstract
  • 2012. Impact of treatment on quality of life in early and drug-naive Parkinson's disease: the Norwegian ParkWest study. European Journal of Neurology. 58-58.
  • 2012. A Scandinavian multi-centre study replicates 11 susceptibility loci from genome-wide association studies in Parkinson's disease. European Journal of Neurology. 40-40.
Poster
  • 2019. ORTHOSTATIC HYPOTENSION IN PARKINSON’S DISEASE: A SEVEN-YEAR PROSPECTIVE POPULATION-BASED STUDY .
  • 2018. Hyposmia and cognitive decline in early Parkinson's disease.
  • 2015. Laryngeal response patterns to mechanical insufflation-exsufflation in amyotrophic lateral sclerosis.
  • 2015. Hvordan reagerer strupen ved bruk av hostemaskin hos personer med amyotrofisk lateral sklerose?
  • 2014. Pattern of sedentary behaviour and physical activity in patients with Parkinson’s disease comparing non-fallers to fallers .
  • 2012. Using local binary pattern to classify dementia in MRI.
Academic literature review
  • 2020. Targeting NAD+ in translational research to relieve diseases and conditions of metabolic stress and ageing. 1-6.
  • 2014. Genetisk sammenheng mellom amyotrofisk lateral sklerose og frontotemporal demens. 302-306.
  • 2010. Ny kunnskap om Creutzfeldt-Jakobs sykdom kan gi terapeutiske muligheter. 601-604.
  • 2010. Are dysautonomic and sensory symptoms present in early Parkinson's disease? 72-77.
  • 2009. Neurological examination of cortical function deficits. 58-62.
  • 2004. Parkinsons sykdom: Nevroproteksjon ved COX 2 hemming? 7-8.
  • 2004. Nevroproteksjon av Coenzym Q10 ved Parkinsons sykdom. 9-10.
  • 2004. Fremtidsutsikter for PD-rammede. 36-37.

More information in national current research information system (CRIStin)